brivaracetam
Sign in to saveBrivaracetam, sold under the brand name Briviact among others, is a chemical analog of levetiracetam, a racetam derivative with anticonvulsant (antiepileptic) properties. It has been approved since 2016. It is marketed by the pharmaceutical company UCB. It is used to treat partial-onset seizures with or without secondary generalisation, in combination with other antiepileptic drugs.
Key facts
- Drug.imageL
- Brivaracetam.svg
- Drug.image_classL
- skin-invert-image
- Drug.widthL
- 130
- Drug.imageR
- Brivaracetam ball-and-stick model from xtal 2018.png
- Drug.image_classR
- bg-transparent
- Drug.widthR
- 110
- Drug.tradename
- Briviact, Nubriveo, Brivajoy
- Drug.MedlinePlus
- a616027
- Drug.DailyMedID
- Brivaracetam
- Drug.pregnancy_AU
- B3
- Drug.routes_of_administration
- By mouth, intravenous
- Drug.ATC_prefix
- N03
- Drug.ATC_suffix
- AX23
- Drug.legal_AU
- S4
- Drug.legal_BR
- C1
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Schedule V
- Drug.legal_EU
- Rx-only
via Wikipedia infobox
Article
12 sectionsContents
- Medical uses
- Adverse effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Pharmacogenetics
- Chemical and physical properties
- History
- Society and culture
- References
- Further reading
Brivaracetam, sold under the brand name Briviact among others, is a chemical analog of levetiracetam, a racetam derivative with anticonvulsant (antiepileptic) properties. It has been approved since 2016. It is marketed by the pharmaceutical company UCB. It is used to treat partial-onset seizures with or without secondary generalisation, in combination with other antiepileptic drugs.
==Medical uses== Brivaracetam is used to treat partial-onset seizures with or without secondary generalisation, in combination with other antiepileptic drugs. Efficacy and tolerability is comparable in general and Intellectual Disability populations. No data are available for its effectiveness and safety in people younger than 16 years of age.